Schwab Fundamental US Small Co. Index ETF
FNDA - ETF AI Analysis
Top Page
Schwab Fundamental US Small Co. Index ETF (FNDA)
FNDA, the Schwab Fundamental US Small Co. Index ETF, has a solid overall rating driven by several strong, profitable holdings like Royalty Pharma, FactSet Research, Abercrombie & Fitch, and Exelixis, which all show healthy financial performance and positive earnings sentiment. At the same time, weaker names such as Etsy and Acadia Healthcare, with issues like declining profitability, financial instability, and bearish technical signals, weigh on the fund’s score. The main risk factor is exposure to smaller companies where mixed technical trends, leverage, and profitability challenges can make returns more volatile.
FNDA vs. SPDR S&P 500 ETF (SPY)
- AUM
- 9.02B
- Region
- North America
- Expense Ratio
- 0.25%
- Beta
- 0.92
- Issuer
- Schwab
- Inception Date
- Aug 15, 2013
- Dividend Yield
- 1.22%
- Asset Class
- Equity
- Index Tracked
- RAFI Fundamental High Liquidity US Small Index - Benchmark TR Gross
FNDA Summary
FNDA is the Schwab Fundamental US Small Co. Index ETF, which follows the RAFI Fundamental High Liquidity US Small Index. It focuses on smaller U.S. companies across many industries, including technology, retail, finance, and health care. Some well-known names in the fund are Abercrombie & Fitch, Etsy, and Twilio. Investors might consider FNDA if they want growth potential and diversification through a wide mix of small companies chosen based on business strength, not just size. A key risk is that small-company stocks can be more volatile, so the ETF’s value can go up and down sharply with the market.
How much will it cost me?
FNDA has an expense ratio of 0.25%, which means you’ll pay about $2.50 per year for every $1,000 invested. This cost is slightly higher than the cheapest broad index ETFs, but still reasonable because it uses a more complex fundamental indexing strategy rather than a simple passive market-cap approach.
What would affect this ETF?
FNDA could benefit if the U.S. economy stays healthy, consumer spending remains strong, and technology and industrial companies continue to grow, supporting many of its small-cap holdings like retailers, software firms, and energy producers. On the downside, rising interest rates, an economic slowdown, or tighter financial and regulatory conditions could hurt smaller U.S. companies more than large ones, increasing volatility for this ETF given its focus on cyclical sectors such as consumer, financials, and real estate.
FNDA Top 10 Holdings
FNDA’s story is driven by a handful of rising U.S. small caps across tech, consumer, and health care. Fashion names like Abercrombie & Fitch and Victoria’s Secret have been powering ahead, giving the fund a stylish tailwind, while Etsy’s rebound adds extra spark despite some underlying business challenges. On the tech side, Twilio and Veeva Systems are climbing on solid growth narratives, though their rich valuations can make the ride bumpy. Exelixis and Royalty Pharma provide steadier health care strength, helping balance out more volatile small-cap swings.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ANF | Abercrombie Fitch | 0.47% | $41.00M | $6.35B | 114.87% | 78Outperform |
 VSXY | Victoria's Secret | 0.47% | $40.85M | $8.62B | 216.52% | 71Outperform |
 FDS | Factset Research | 0.41% | $35.77M | $11.56B | 22.97% | 78Outperform |
 ACHC | Acadia Healthcare | 0.37% | $32.87M | $3.44B | 112.66% | 61Neutral |
 RPRX | Royalty Pharma | 0.37% | $32.49M | $38.61B | 80.20% | 79Outperform |
 VEEV | Veeva Systems | 0.36% | $31.68M | $49.18B | 3.31% | 66Neutral |
 ETSY | Etsy | 0.35% | $30.96M | $7.75B | 43.59% | 57Neutral |
 EXEL | Exelixis | 0.35% | $30.53M | $16.98B | 70.44% | 78Outperform |
 COMP | Compass | 0.34% | $29.48M | $7.84B | 13.65% | 61Neutral |
FNDA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FNDA, the sentiment is Negative. The current price of 36.36 is above the 20-day moving average (MA) of 35.81, above the 50-day MA of 35.90, and above the 200-day MA of 35.47, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 44.74 is Neutral, neither overbought nor oversold. The STOCH value of 36.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FNDA.
FNDA Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FNDA | $36.36 | $39.00(7.26% Upside) | $9.02B | 0.25% | 67Neutral |
 FESM | $45.58 | $57.52(26.19% Upside) | $6.64B | 0.28% | 64Neutral |
 SMLF | $85.79 | $103.75(20.93% Upside) | $4.28B | 0.15% | 66Neutral |
 VIOO | $131.41 | $156.28(18.92% Upside) | $4.19B | 0.07% | 66Neutral |
 CALF | $57.68 | $64.85(12.43% Upside) | $3.86B | 0.59% | 65Neutral |
 ESML | $54.08 | $63.90(18.15% Upside) | $2.78B | 0.17% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FNDA | Schwab Fundamental US Small Co. Index ETF | 36.36 | 5.74 | 18.75% | |
| FESM | Fidelity Enhanced Small Cap ETF | 45.58 | 8.64 | 23.38% | |
| SMLF | iShares MSCI USA Small-Cap Multifactor ETF | 85.79 | 11.96 | 16.20% | |
| VIOO | Vanguard S&P Small-Cap 600 ETF | 131.41 | 21.71 | 19.79% | |
| CALF | Pacer US Small Cap Cash Cows 100 ETF | 57.68 | 14.24 | 32.80% | |
| ESML | iShares ESG Aware MSCI USA Small-Cap ETF | 54.08 | 9.13 | 20.32% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.